Clinical guidelines recommend microsatellite instability (MSI) and BRAF V600E testing of all colorectal cancers (CRCs) to screen for Lynch syndrome (LS), a hereditary predisposition to cancer. MSI is also associated with response to immunotherapy. However, uptake of MSI testing is poor and current assays are not suitable for high throughput diagnostics.
Introduction
Colorectal cancer (CRC) is the third most common cancer in Western society 1 .
Approximately 1 in 6 CRCs have genome-wide insertion-deletion mutation in >30% of microsatellites, defined as high microsatellite instability (MSI-high) 2 , a phenotypic manifestation of deficiency of the mismatch repair (MMR) system 3 . Lynch syndrome (LS) is a cancer-predisposition syndrome caused by germline pathogenic variants affecting one of four MMR genes, with a lifetime cancer risk up to 70% 4 . The LS cancer spectrum includes CRC, endometrial cancer and others. Clinical management of LS includes 1-2 yearly surveillance colonoscopy, prophylactic surgery 5 , and chemoprevention using daily aspirin 6 .
Following the two hit hypothesis of tumour progression, nearly all LS CRCs are MMR deficient (MMRd) 7 . Guidelines from the UK National Institute of Health and Care Excellence 8 and others 9 advocate that all CRCs should be tested for MMR deficiency to screen for LS.
BRAF V600E or MLH1 methylation testing increases the specificity of LS screening by removing sporadic MMRd CRCs 10, 11 . MMR deficiency can also inform choice of therapy as affected CRCs are sensitive to immune checkpoint blockade 12 , which is FDA-approved as a second line therapeutic for any MSI-high solid cancer 13 .
The dominant MMR deficiency tests are MSI detection by PCR fragment length analysis (FLA), or assessment of MMR protein expression by immunohistochemistry (IHC). FLA using panels exclusively composed of mononucleotide repeats (MNRs) achieves sensitivity and specificity of 97% and 100% respectively 14 and IHC of all 4 MMR proteins has 93% sensitivity and 95% specificity 15 . IHC misses approximately 5% of MMRd CRCs 14 , due to mutations that lead to loss of MMR function but retain antigenicity 15 . A high accuracy, diagnostic test should also be robust to sample variables, be reproducible and meet clinical demands such as rapid turnaround time and low cost. FLA has 98% reproducibility between independent laboratories 16 , whilst IHC shows greater heterogeneity in results interpretation 15 . Both are considered accurate for tumour cell content >10% 17 
and the National Institute of Health
Research Health Technology Assessment found both to be cost-effective within the LS screening pipeline, with incremental cost-effectiveness ratios <£20,000 per quality-adjusted life year gained 18 . However, testing all CRCs to screen for LS, and predictive testing of any cancer for response to immune checkpoint blockade therapy, will require scalable assays.
IHC and FLA are limited by reliance on case-by-case result analysis, with IHC needing trained pathologists to assess variable staining patterns 15 and FLA needing experienced operators to interpret PCR "stutter" peaks generated by the error-prone markers used 16 . Due to the unsuitability of current assays for high throughput, the uptake of MMR deficiency testing has been poor: only 28% of 152,993 CRC cases were tested between 2010-2012 in the USA 19 despite concurrent estimation that only 1.2% of the LS gene carrier population was known 20 and over a decade of testing recommendations 9 .
Next generation sequencing (NGS) of tumours to diagnose MSI have been developed with sensitivities and specificities of >95% 21 . Tumour-sequencing could reduce the recommended LS screening pipeline to two steps (tumour-sequencing and germline confirmation) by simultaneous detection of MSI, BRAF V600E and MMR gene mutations 22 . Coupled tumour and germline-sequencing can also determine the somatic origin of MMR deficiency in 52% of Lynch-like tumours with double somatic MMR mutations, which may avoid unnecessary management of these CRCs as LS 23 . However the cost of tumour-sequencing is a barrier to its deployment, with an estimate of 607±207€ per sample in a recent French, nationwide study of tumour-sequencing in clinical practice 24 . Cheaper assays that target multiple, clinically actionable markers are needed. MSIplus, for example, is a targeted NGS-based assay analysing MSI, BRAF and RAS gene mutations, but includes long (up to 28bp) and error prone microsatellite markers 25 . Furthermore, the robustness of NGS-based MSI assays to multiple sample variables are rarely or inadequately assessed, with a lack of quality control to ensure results reliability, which is desirable for deployment of assays into the clinic 26 .
We have recently published a PCR and NGS-based assay for MSI that utilises a novel set of short (7-12bp) and monomorphic MNRs, selected to reduce PCR and sequencing error and ease interpretation relative to longer markers 27, 28 . SNPs neighbouring each of the microsatellites are used to determine allelic bias of instability in heterozygote patients, increasing signal-noise discrimination. A naïve Bayesian MSI classifier was developed for these markers which has ≥97% sensitivity and specificity relative to microsatellite FLA 29 .
Here, we create a fully automatable, modular, and cheap MSI assay, suitable for high throughput MMR diagnostics and two-step screening for LS, by multiplex amplification of our markers and the BRAF V600E locus using single molecule molecular inversion probe (smMIP) technology 30 . smMIPs have previously been used to multiplex large panels of long (16-40bp) microsatellites 31 , and read-tagging with molecular barcodes provides a count of template molecules sequenced as a quality control 32 . We show that our smMIP-based MSI assay has 100% sensitivity and specificity for MMR deficiency relative to FLA, and detects BRAF V600E mutations missed by conventional techniques. MSI calling is reproducible and robust to sample variables, with accurate classification of DNA equivalent to 3% MMRd tumour cell content and from a minimum sequencing depth of 75 template DNA molecules per marker. 19 DNAs extracted from peripheral blood lymphocytes from patients with no evidence of familial cancer syndromes, consented for sample use for assay development, were used as microsatellite stable (MSS) controls.
Materials and Methods
All CRC samples were independently tested for MMR deficiency by MSI Analysis System v1.2 (Promega) in the contributing pathology laboratory.
All samples were anonymised by the contributing laboratories.
Cell Lines and Cell Culture
DNA from embryonic stem cell H9 was a gift from L. Lako (Newcastle University, UK), and was used as an MSS control.
Both HCT116 and K562 cells were gifted by the Irving Research Group (Newcastle University, UK). HCT116 CRC cell line, containing hemizygous MLH1 truncation, was used as an MSI-high control. K562 chronic myeloid leukaemia cell line was used as an MSS control. HCT116 and K562 cells were grown in RPMI growth medium containing 2mM L-glutamine (Gibco), 10% fetal bovine serum (Gibco), 60µg/ml penicillin and 100µg/ml streptomycin (Gibco) at 37°C and 5% CO2. HCT116 cells were split and harvested at 80-90% confluence by decanting expired growth medium, washing in 5ml PBS (Gibco) and detaching cells using 0.05% Trypsin-EDTA (Gibco). K562 cells were split and harvested at a density of 1x10 6 cells/ml.
DNA Extraction and Quantification
DNA was extracted from FFPE CRC tissue using the GeneRead DNA FFPE Kit (QIAGEN).
DNA was extracted from cell lines using the Wizard Genomic DNA Purification Kit (Promega).
DNAs were quantified using QuBit 2.0 Fluorometer (Invitrogen) and QuBit dsDNA BR/HS Kits (Invitrogen).
Marker Selection
A total of 24 MNRs with length 7-12bp and neighbouring SNP 29 were selected to test for MMR deficiency. BRAF V600E was included to screen for sporadic MMRd CRCs.
smMIP Design
MIPgen 34 was used to generate smMIPs for each marker using reference genome hg19, indexed with SAMtools v1.3 and BWA v0.7.12, and a bed file of marker loci (Supplement S1).
MIPgen parameters were: tag size 6,0, minimum capture size 120, and maximum capture size 150. seconds, and 72°C for 30 seconds, followed by 72°C for 2 minutes. smMIP reaction products (240-270bp) were analysed using agarose gel electrophoresis (3% gel run at 80mV for 60 minutes) or QIAxcel (QIAGEN) using method AL420. Libraries were sequenced using the MiSeq platform (Illumina) with the GenerateFastq workflow, paired end sequencing, and smMIP custom sequencing primers 30 .
Library Preparation and Sequencing

Sequencing Read Analysis and MSI Classification
Sequencing reads from MiSeq-generated fastq files were aligned to hg19 using BWA v0.6.2 35 . Variants in microsatellite length, SNP and mutation hotspot loci were identified from .sam files, and only variants observed on both reads of a pair were tabulated by custom R scripts.
The MSI classifier used custom R scripts and the algorithm previously described by Redford et al 29 . In summary, to determine the relative probability that a sample is modelled by an MMRd versus an MMRp phenotype, both the proportion of reads containing microsatellite deletions and the allelic bias of deletions are used. Scores >0 classify a sample as MMRd (MSI-high). The algorithm is trained in one cohort of samples and validated in a second, independent cohort. Custom R scripts were used for all other analyses of reads and variants (available upon request).
Statistics and Graphics
Statistical tests and graph generation was performed in R (v3.3.1), utilising R package ggplot2.
Results
MSI Status is Accurately and Reproducibly Classified
To train the MSI classifier algorithm, 24 microsatellite and BRAF V600E markers were amplified from 51 MMRd CRCs, 47 MMRp CRCs, and HCT116 and H9 cell lines as MSI-high and MSS controls (see methods). Amplicons were sequenced to a mean read depth (±sd) of 3719±3149 reads/marker/sample with 75.3% of base-calls ≥Q30. The trained MSI classifier subsequently typed these same samples with 100% sensitivity (95% CIs: 93.0-100.0%) and 100% specificity (95% CIs: 92.5-100.0%) ( Figure 1A) . Classification by the most discriminatory 6 microsatellites also achieved 100% accuracy, suggesting marker redundancy ( Figure 1A) .
A read-balanced smMIP pool, based on per marker read depths from the training cohort, was created to equalise the number of reads generated from each marker (Supplement S3).
50 MMRd CRCs and 49 MMRp CRCs were then amplified as an independent validation cohort (see methods), and sequenced to a mean read depth (±sd) of 7320±4192 reads/marker/sample with 57.2% of base-calls ≥Q30. The MSI classifier achieved 100% sensitivity (95% CIs: 92.9-100.0%) and 100% specificity (95% CIs: 92.8-100.0%) using either 24 microsatellites or the 6 most discriminatory microsatellites identified from the training cohort ( Figure 1B) .
To assess assay reproducibility, 16 MMRd and 16 MMRp CRCs from the validation cohort were amplified a second time using a new read-balanced smMIP pool, again targeting the 24 microsatellite markers and BRAF V600E. These amplicons were sequenced to a mean read depth (±sd) of 5408±2160 reads/marker/sample with 85.4% of base-calls ≥Q30.
Classification was 100% concordant with previous results and classifier scores were strongly correlated between sample repeats (β = 0.97, p < 10 -16 , R 2 = 0.97).
BRAF V600E is Detectable at Low Variant Frequencies
All of the 14 CRCs that tested positive for BRAF V600E by HRM had ≥5% mutant reads assigned to the BRAF V600E locus using the smMIP-based sequencing assay. Of the 32 CRCs that tested negative for BRAF V600E by HRM, 30 samples had BRAF V600E detected in ≤0.6% of reads and 2 samples had BRAF V600E detected in 1.67% and 1.72% of reads, suggesting these 2 samples may contain true mutations not detected by HRM.
Using a ≥1% mutant read threshold, BRAF V600E was detected in 9. 
MSI Classification is Robust to Low MSI-high Content
To assess the lower limit of detection (LLoD), defined here as the lowest proportion of MSIhigh DNA within total template DNA at which a sample is classified as MSI-high, a DNAmixture series of 0.78-100% MSI-high DNA content (log2 increments) was created in triplicate, by mixing HCT116 MSI-high DNA into control MSS DNA extracted from peripheral blood leukocytes. This triplicate series and control MSS DNAs were amplified using a readbalanced smMIP pool. Amplicons were sequenced to a mean read depth (±sd) of 4763±1288 reads/marker/sample with 84.7% of base-calls ≥Q30.
Increasing the MSI-high DNA content of the template DNA increased the proportion of reads containing insertion-deletion mutations in the microsatellite (Figure 2A) ; the observed and the expected proportions (Supplement S4) were strongly correlated (β = 1.009, p = 2x10 -16 , R 2 = 0.996, Figure 2B ), giving confidence in the accuracy of the DNA-mixture series. MSI classification of the DNA-mixture series was accurate from 3.13% or more MSI-high content in each replicate series ( Figure 2C ), approximating the LLoD to 3%. To compare with FLA, replicates ranging from 1.56-12.5% MSI-high DNA content were independently classified using the MSI Analysis System (Promega), with the observer blinded to both sample content and experimental purpose. FLA reliably detected 6.25% MSI-high DNA content (Table 1) .
MSI Classification is Reliable from sequencing 75 Molecules per Marker
To establish the lowest quantity of template DNA required for accurate smMIP-based classification, 2-fold dilution (0.78-100ng) series of 9 DNA samples, comprising 3 cell lines (HCT116, K562 and H9), 3 MMRd CRCs and 3 MMRp CRCs, were amplified using a readbalanced smMIP pool. Samples were selected based on availability of residual DNA.
Amplicons generated from 3.13-100ng of template DNA, selected by visual detection of the reaction products (Supplement S5), were sequenced to a mean read depth (±sd) of 243,073±64,485 reads/sample with 82.8% of base-calls ≥Q30.
The number of template molecules sequenced, as measured by the number of molecular barcodes detected, was compared to the input quantity of DNA of the 9 samples, and the two were closely correlated (β = 0.84-0.96, p < 10 -3 , R 2 = 0.986-0.997, Figure 3A) , giving confidence in the dilution series. The MSI classifier accurately typed samples using ≥12.5ng of template DNA ( Figure 3B ). However, two MMRd CRC samples (207950 and 244881) showed large changes in classifier score between 12.5ng and 25ng of template DNA. These samples were derived from FFPE tissue, suggesting that low quality DNA may be responsible for the variation in classifier score. This was supported by the lower number of molecular barcodes detected in these two samples ( Figure 3A ). Comparison of classifier scores with the mean number of molecular barcodes detected suggested that sequencing a minimum of 75 template molecules per marker is sufficient to reliably classify these samples ( Figure 3C ).
Discussion
Our smMIP-based MSI assay uses monomorphic and short (7-12bp) MNRs that have significantly lower PCR and sequencing error rates compared to longer markers 27 , including those used by the MSI Analysis System (Promega) and NGS-based assays 25, 31 . Automated MSI classification from sequencing only tumour DNA achieved 100% sensitivity and 100% specificity relative to microsatellite FLA in 197 CRCs. smMIP-based sequencing of short MNRs fulfils other requirements of an ideal diagnostic test 26 , such as 100% classification concordance in repeat testing and robustness to common sample variables, including low MSI-high DNA content (LLoD approximated to 3%) and applicability to poor quality sample DNA from FFPE tissue. The assay LLoD was also superior to that of the MSI Analysis System (Promega). Furthermore, smMIPs incorporate molecular barcodes into reads allowing the number of sample DNA molecules sequenced to be quantified as a quality control metric. A minimum of 75 molecular barcodes per marker was required for accurate classification.
The inclusion of BRAF V600E in the smMIP-based MSI assay streamlines the LS screening pipeline, requiring only one tumour test prior to germline testing of MMR genes, equivalent to tumour-sequencing 22 . We were able to detect low variant allele frequencies in BRAF down to 1.7%, with improved sensitivity compared to HRM analysis, which has an estimated LLoD of 10% 33 . Using a ≥1% mutant read threshold, our frequency estimates of BRAF V600E in 9.4% and 36.6% of MMRp and MMRd CRCs agrees with the 7% and 31% frequencies previously observed 36 . MLH1 promoter methylation is an alternative test for sporadic cases of MMRd CRC and has a higher specificity than BRAF V600E when screening for LS 37 .
However, testing both markers is redundant due to their association 37 , and MLH1 methylation testing reduces sensitivity for LS by deselection of MLH1 mutation carriers that have methylation as a second hit 38 or germline epimutations 39 . This was also observed by Hampel et al 22 , and explains the reduced sensitivity of current screening practice relative to tumour-sequencing. We also multiplexed smMIPs targeting KRAS codons 12 and 13 mutations within our assay (Supplement S6). Whilst this does not cover the full scope of RAS gene mutations, it highlights the robustness of smMIPs to multiplexing and the ease with which additional, clinically actionable biomarkers can be added to the assay.
The cost of a diagnostic assay is a significant factor in its clinical uptake. Tumour-sequencing for example, has an estimated cost of 607±207€ per sample 24 , significantly more than a targeted assay such as our smMIP-based MSI assay. Our assay has an equivalent reagent cost to FLA when using 24 microsatellite plus BRAF markers, ranging from £8.20-£32.60 depending on the capacity of the MiSeq kit used (Supplement S7). As 6 microsatellites were sufficient for accurate MSI classification these costs can be reduced further. The smMIP protocol can also be fully automated and ported to the higher throughput NextSeq platform 40 (Supplement S8) . Furthermore, BRAF V600E testing is included within the assay, avoiding expenditure on additional tests for LS screening.
In summary, our smMIP-based MSI assay is highly sensitive and specific for MMR deficiency in CRC, simultaneously detects BRAF V600E, is reproducible, and is robust to sample variables. The automation of laboratory workflow and result interpretation removes the need for expert personnel, and provides a cheap, scalable assay. Combined, these factors suggest that a high throughput smMIP-based MSI assay is a suitable companion diagnostic for immune checkpoint blockade therapy and is applicable to two-step LS screening strategies. The proportion of reads containing insertion-deletion mutations in microsatellites increases as the MSI-high DNA content increases in the sample. This is shown for three markers: GM29, representative of markers that are un-mutated or sub-clonally mutated in the MSI-high DNA; IM16, representative of markers that are heterozygous mutated in the MSI-high DNA; and LR17, representative of markers that are homozygous mutated in the MSI-high DNA. (B) Across DNA-mixture samples of varying MSI-high DNA content, the observed and the expected proportions of reads with a mutant microsatellite correlate very closely with expected values. (C) The MSI classifier calls MSI-high with 100% accuracy in samples with ≥3.13% MSI-high DNA content. However, at 3.13% MSI-high DNA content the pathologist was uncertain of the status of all 5 markers. Therefore, confident classification as MSI-high was only achieved in samples with ≥6.25% MSI-high DNA content. These same samples were analysed using our smMIP and NGS-based MSI assay. 
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